Table 2.
Clinical Success Rates at TOC (10 to 45 Days Post-Therapy) in Patients with Secondary Peritonitis in the Pooled Analysis of cIAIs
| Study | Moxifloxacin n/N (%) | Comparators n/N (%) | 95% CI (%, %) | Point estimate (%) | Relative weight | Heterogeneity |
|---|---|---|---|---|---|---|
| PP populations | ||||||
| Malangoni (2000–2003, USA)13 | 66/89 (74.2) | 57/73 (78.1) | −17.07–9.22 | −3.92 | 15.74% | 0.02 (0.58%) |
| Weiss (2001–2002, Europe)14 | 92/111 (82.9) | 110/135 (81.5) | −8.19–10.99 | 1.40 | 23.90% | 0.81 (25.25%) |
| Solomkin (2005–2007, Asia)15 | 18/24 (75.0) | 28/30 (93.3) | −37.82–1.15 | −18.33 | 5.23% | 2.38 (73.93%) |
| De Waele (2006–2009, Europe)16 | 255/281 (90.7) | 264/281 (94.0) | −7.59–1.18 | −3.20 | 55.13% | < 0.01 (0.24%) |
| Total | 431/505 (85.3) | 459/519 (88.4) | −7.06–1.05 | −3.01 | Chi2=3.21 p value=0.360* |
|
| ITT populations | ||||||
|---|---|---|---|---|---|---|
| Malangoni (2000–2003, USA)13 | 69/129 (53.5) | 63/122 (51.6) | −10.51–14.21 | 1.85 | 20.46% | 0.85 (20.94%) |
| Weiss (2001–2002, Europe)14 | 93/127 (73.2) | 114/152 (75.0) | −12.10–8.56 | −1.77 | 22.58% | 0.17 (4.27%) |
| Solomkin (2005–2007, Asia)15 | 18/26 (69.2) | 28/31 (90.3) | −41.66–−0.52 | −21.09 | 4.61% | 2.66 (65.61%) |
| De Waele (2006–2009, Europe)16 | 269/327 (82.3) | 277/315 (87.9) | −11.16–−0.19 | −5.67 | 52.35% | 0.37 (9.18%) |
| Total | 449/609 (73.7) | 482/620 (77.7) | −8.54–0.61 | −3.96 | Chi2=4.06 p value=0.255* |
|
CI=confidence interval; cIAI=complicated intra-abdominal infections; ITT=intent-to-treat; PP, per-protocol; TOC=test-of-cure. *P value refers to heterogeneity test and not to comparison of clinical efficacy between treatment groups.